22157.jpg
Gene Therapy Market, 2035
09 août 2022 07h53 HE | Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Type of Therapy, Type of Gene Delivery Method Used, Type of Vector Used, Target Therapeutic Areas, Route of Administration, and...
Straits Research Pvt Ltd
CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
01 août 2022 12h40 HE | Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
Insights on the Genome Editing Global Market to 2027 - Growing Cases of Cancer and Other Genetic Disorders is Driving Growth
22 juin 2022 06h03 HE | Research and Markets
Dublin, June 22, 2022 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. Genome editing is a method of making...
Intellia.jpg
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
02 mai 2022 07h30 HE | Intellia Therapeutics, Inc.
Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapyFindings support recent development candidate...
Global CRISPR Technology Market Analysis 2022-2026, Featuring Profiles of Thermo Fisher Scientific, CRISPR Therapeutics, GenScript Biotech, Editas Medicine and Intellia Therapeutics
19 avr. 2022 04h08 HE | Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2022, By Product Type, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering....
Global Gene Editing Market Analysis 2022-2026, Featuring Profiles of CRISPR, GenScript, Thermo Fisher Scientific, Merck and AstraZeneca
19 avr. 2022 04h03 HE | Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing Global Market Report 2022, By Technology, By End Users, By Application" report has been added to ResearchAndMarkets.com's offering. The...
Global $14.9 Bn Nucleic Acid Based Gene Therapy Markets, 2015-2020, 2025F, 2030F
07 avr. 2022 04h58 HE | Research and Markets
Dublin, April 07, 2022 (GLOBE NEWSWIRE) -- The "Nucleic Acid Based Gene Therapy Global Market Opportunities And Strategies To 2030, By Nucleic Acid Technology, Application, End User" report has been...
22157.jpg
Global Gene Editing Beyond CRISPR Market (2022 to 2035) - Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies
22 mars 2022 06h13 HE | Research and Markets
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing beyond CRISPR Market: Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies:...
Intellia.jpg
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia 
09 mars 2022 16h01 HE | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia.jpg
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
28 févr. 2022 16h01 HE | Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...